Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 19,078 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Clear all
Terminated Phase 3 Interventional Results available

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640
View directory record Official record
Conditions
Covid19
Interventions
BNT162b2 vaccine, JNJ-78436735 Vaccine
Biological
Lead sponsor
Giselle Guerra
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 17, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Atacicept in Subjects With Optic Neuritis

NCT00624468
View directory record Official record
Conditions
Optic Neuritis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 17, 2026, 5:14 PM EDT
Terminated No phase listed Observational

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

NCT05414123
View directory record Official record
Conditions
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
CNSide
Device
Lead sponsor
Biocept, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

NCT00752180
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin R, Actrapid
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

NCT03255096
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
Interventions
RO6870810, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Duarte, California • Stanford, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 17, 2026, 5:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Biobehavioral Mechanisms of Food Insecurity

NCT04968496
View directory record Official record
Conditions
Food Insecurity, Obesity, Childhood, Inflammation, Mental Health
Interventions
Food Secure Group
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
8 Years to 12 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newport, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Natural Killer (NK) Cell Transplantation for AML

NCT00187096
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
Drug · Procedure · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

NCT00019396
View directory record Official record
Conditions
Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
Interventions
flt3 ligand, gp100 antigen, MART-1 antigen, Montanide ISA-51, tyrosinase peptide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 17, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

NCT00183976
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Burkitt Lymphoma, Primary Effusion Lymphomas
Interventions
Pegylated Liposomal Doxorubicin (Doxil) and Rituximab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 17, 2026, 5:14 PM EDT
Not listed Not applicable Interventional

Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion

NCT00005889
View directory record Official record
Conditions
Infant, Low Birth Weight, Hyperglycemia
Interventions
alanine, amino acids, glucagon, glucose, glutamine, glycerol, insulin, leucine, lipids, urea
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
4 Days to 6 Days
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 5:14 PM EDT
Completed No phase listed Observational

Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia

NCT00914550
View directory record Official record
Conditions
Pneumonia, Radiographic Lung Infiltrates
Interventions
Procalcitonin level, caregiver informed
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 17, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018
View directory record Official record
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
Interventions
Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Foxborough, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

NCT01363297
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
Inotuzumab Ozogamicin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab to Treat Severe Aplastic Anemia

NCT00195624
View directory record Official record
Conditions
Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia, Relapse
Interventions
Alemtuzumab (Campath ), Cyclosporine
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 110 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers

NCT01779024
View directory record Official record
Conditions
fMRI, Alcohol Drinking, Alcoholism
Interventions
Ghrelin, Placebo, fMRI, Alcohol
Drug · Procedure
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 17, 2026, 5:14 PM EDT
Not listed Not applicable Interventional

Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics

NCT02299882
View directory record Official record
Conditions
Lumbar Pain
Interventions
Vancomycin
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 17, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

NCT06785324
View directory record Official record
Conditions
Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL
Interventions
Nutrition Intervention, Exercise intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 17, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

NCT01756924
View directory record Official record
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
Interventions
CEM-102, IV or Oral standard of care antibiotics, Rifampin
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 17, 2026, 5:14 PM EDT
Not listed No phase listed Observational

A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue

NCT05268224
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
Schirmer Strip
Diagnostic Test
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 17, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

NCT01061515
View directory record Official record
Conditions
Carcinoma
Interventions
Intraperitoneal Oxaliplatin, Bevacizumab, Capecitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Angiosarcoma

NCT00288015
View directory record Official record
Conditions
Sarcoma
Interventions
Bevacizumab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
5
States / cities
La Jolla, California • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 17, 2026, 5:14 PM EDT
Not listed Phase 1Phase 2 Interventional

Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

NCT00184015
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Bevacizumab and Bortezomib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Efprezimod alfa, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 17, 2026, 5:14 PM EDT